APA

Scott J. D., DeMong D. E., Greshock T. J., Basu K., Dai X., Harris J., Hruza A., Li S. W., Lin S., Liu H., Macala M. K., Hu Z., Mei H., Zhang H., Walsh P., Poirier M., Shi Z., Xiao L., Agnihotri G., Baptista M. A. S., Columbus J., Fell M. J., Hyde L. A., Kuvelkar R., Lin Y., Mirescu C., Morrow J. A., Yin Z., Zhang X., Zhou X., Chang R. K., Embrey M. W., Sanders J. M., Tiscia H. E., Drolet R. E., Kern J. T., Sur S. M., Renger J. J., Bilodeau M. T., Kennedy M. E., Parker E. M., Stamford A. W., Nargund R., McCauley J. A. & Miller M. W. (20170424). Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. : Journal of medicinal chemistry.

Chicago

Scott Jack D, DeMong Duane E, Greshock Thomas J, Basu Kallol, Dai Xing, Harris Joel, Hruza Alan, Li Sarah W, Lin Sue-Ing, Liu Hong, Macala Megan K, Hu Zhiyong, Mei Hong, Zhang Honglu, Walsh Paul, Poirier Marc, Shi Zhi-Cai, Xiao Li, Agnihotri Gautam, Baptista Marco A S, Columbus John, Fell Matthew J, Hyde Lynn A, Kuvelkar Reshma, Lin Yinghui, Mirescu Christian, Morrow John A, Yin Zhizhang, Zhang Xiaoping, Zhou Xiaoping, Chang Ronald K, Embrey Mark W, Sanders John M, Tiscia Heather E, Drolet Robert E, Kern Jonathan T, Sur Sylvie M, Renger John J, Bilodeau Mark T, Kennedy Matthew E, Parker Eric M, Stamford Andrew W, Nargund Ravi, McCauley John A and Miller Michael W. 20170424. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. : Journal of medicinal chemistry.

Harvard

Scott J. D., DeMong D. E., Greshock T. J., Basu K., Dai X., Harris J., Hruza A., Li S. W., Lin S., Liu H., Macala M. K., Hu Z., Mei H., Zhang H., Walsh P., Poirier M., Shi Z., Xiao L., Agnihotri G., Baptista M. A. S., Columbus J., Fell M. J., Hyde L. A., Kuvelkar R., Lin Y., Mirescu C., Morrow J. A., Yin Z., Zhang X., Zhou X., Chang R. K., Embrey M. W., Sanders J. M., Tiscia H. E., Drolet R. E., Kern J. T., Sur S. M., Renger J. J., Bilodeau M. T., Kennedy M. E., Parker E. M., Stamford A. W., Nargund R., McCauley J. A. and Miller M. W. (20170424). Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. : Journal of medicinal chemistry.

MLA

Scott Jack D, DeMong Duane E, Greshock Thomas J, Basu Kallol, Dai Xing, Harris Joel, Hruza Alan, Li Sarah W, Lin Sue-Ing, Liu Hong, Macala Megan K, Hu Zhiyong, Mei Hong, Zhang Honglu, Walsh Paul, Poirier Marc, Shi Zhi-Cai, Xiao Li, Agnihotri Gautam, Baptista Marco A S, Columbus John, Fell Matthew J, Hyde Lynn A, Kuvelkar Reshma, Lin Yinghui, Mirescu Christian, Morrow John A, Yin Zhizhang, Zhang Xiaoping, Zhou Xiaoping, Chang Ronald K, Embrey Mark W, Sanders John M, Tiscia Heather E, Drolet Robert E, Kern Jonathan T, Sur Sylvie M, Renger John J, Bilodeau Mark T, Kennedy Matthew E, Parker Eric M, Stamford Andrew W, Nargund Ravi, McCauley John A and Miller Michael W. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. : Journal of medicinal chemistry. 20170424.